Published in Bone on September 17, 2010
WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med (2013) 4.52
Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med (2013) 1.90
The osteocyte: an endocrine cell ... and more. Endocr Rev (2013) 1.84
Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res (2013) 1.29
LRP5 and LRP6 in development and disease. Trends Endocrinol Metab (2013) 1.21
Mesenchymal Stem Cells in Bone Regeneration. Adv Wound Care (New Rochelle) (2013) 1.18
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res (2013) 1.07
Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology (2011) 1.02
Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies. Curr Osteoporos Rep (2012) 0.99
Connexin 43 deficiency attenuates loss of trabecular bone and prevents suppression of cortical bone formation during unloading. J Bone Miner Res (2012) 0.98
Wnt signaling and orthopedics, an overview. Acta Orthop (2011) 0.95
Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats. Acta Orthop (2011) 0.94
Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am (2013) 0.93
Sclerostin Inhibition in the Management of Osteoporosis. Calcif Tissue Int (2016) 0.92
Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast. Mol Cell Biol (2015) 0.92
Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? Osteoporos Int (2014) 0.90
Bone biology and anabolic therapies for bone: current status and future prospects. J Bone Metab (2014) 0.90
A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am (2014) 0.89
Load regulates bone formation and Sclerostin expression through a TGFβ-dependent mechanism. PLoS One (2013) 0.89
The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b. J Bone Miner Res (2014) 0.88
Combined effects of botulinum toxin injection and hind limb unloading on bone and muscle. Calcif Tissue Int (2013) 0.88
Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis. Front Endocrinol (Lausanne) (2015) 0.84
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta. J Bone Miner Res (2016) 0.82
Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int (2015) 0.82
The osteocyte as a therapeutic target in the treatment of osteoporosis. Ther Adv Musculoskelet Dis (2014) 0.82
Influence of body weight on bone mass, architecture and turnover. J Endocrinol (2016) 0.80
Novel approaches for two and three dimensional multiplexed imaging of osteocytes. Bone (2015) 0.79
Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions. Curr Osteoporos Rep (2014) 0.79
Inhibitors of sclerostin: emerging concepts. Curr Opin Rheumatol (2014) 0.78
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats. Sci Rep (2015) 0.78
Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse. Bone (2016) 0.77
Biomechanical aspects of the muscle-bone interaction. Curr Osteoporos Rep (2015) 0.77
Bone health in patients with multiple sclerosis. J Osteoporos (2011) 0.76
The Skeletal Cell-Derived Molecule Sclerostin Drives Bone Marrow Adipogenesis. J Cell Physiol (2017) 0.75
Application of anti-Sclerostin therapy in non-osteoporosis disease models. Bone (2016) 0.75
Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse. Bone (2016) 0.75
Missense Mutations in LRP5 Associated with High Bone Mass Protect the Mouse Skeleton from Disuse- and Ovariectomy-Induced Osteopenia. PLoS One (2015) 0.75
Osteoporosis Therapy: Bone Modeling during Growth and Aging. Front Endocrinol (Lausanne) (2017) 0.75
Effects of anti-sclerostin antibody and running on bone remodeling and strength. Bone Rep (2015) 0.75
Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation. Int J Mol Sci (2017) 0.75
Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury. Osteoporos Int (2016) 0.75
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest (2006) 3.72
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Different functional roles of T1R subunits in the heteromeric taste receptors. Proc Natl Acad Sci U S A (2004) 2.85
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (2006) 2.59
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res (2010) 2.52
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol (2002) 2.35
A transforming metal nanocomposite with large elastic strain, low modulus, and high strength. Science (2013) 2.28
Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem (2002) 2.12
Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet (2005) 2.10
Nebulin-deficient mice exhibit shorter thin filament lengths and reduced contractile function in skeletal muscle. J Cell Biol (2006) 2.00
Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol (2003) 1.93
T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development (2005) 1.92
Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem (2004) 1.91
Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med (2013) 1.90
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med (2011) 1.88
Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol (2005) 1.85
Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother (2010) 1.82
Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev (2012) 1.82
The P2X7 nucleotide receptor mediates skeletal mechanotransduction. J Biol Chem (2005) 1.81
Protocadherin FAT1 binds Ena/VASP proteins and is necessary for actin dynamics and cell polarization. EMBO J (2004) 1.73
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res (2011) 1.70
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res (2010) 1.65
Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem (2009) 1.60
Molecular mechanism for the umami taste synergism. Proc Natl Acad Sci U S A (2008) 1.53
Superhigh-throughput needleless electrospinning using a rotary cone as spinneret. Small (2010) 1.52
Endothelial expression of bone morphogenetic protein receptor type 1a is required for atrioventricular valve formation. Ann Thorac Surg (2008) 1.51
Knowledge and personal use of menopausal hormone therapy among Chinese obstetrician-gynecologists: results of a survey. Menopause (2014) 1.44
Bitter taste receptors influence glucose homeostasis. PLoS One (2008) 1.44
The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes Dev (2012) 1.43
Parallel preoptic pathways for thermoregulation. J Neurosci (2009) 1.43
Impact of 120-W 2-μm continuous wave laser vapoenucleation of the prostate on sexual function. Lasers Med Sci (2013) 1.42
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc Natl Acad Sci U S A (2007) 1.38
Specific alleles of bitter receptor genes influence human sensitivity to the bitterness of aloin and saccharin. Curr Biol (2007) 1.37
Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep (2013) 1.35
Molecular mechanism of the sweet taste enhancers. Proc Natl Acad Sci U S A (2010) 1.32
Nanomechanical characterization of one-step combustion-synthesized Al(4)B(2)O(9) and Al(18)B(4)O(33) nanowires. Nano Lett (2007) 1.31
The effects of Gd3+ substitution on the crystal structure, site symmetry, and photoluminescence of Y/Eu layered rare-earth hydroxide (LRH) nanoplates. Dalton Trans (2011) 1.31
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone (2011) 1.30
Freestanding three-dimensional graphene/MnO2 composite networks as ultralight and flexible supercapacitor electrodes. ACS Nano (2012) 1.30
Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res (2013) 1.29
Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One (2010) 1.29
PINCH1 plays an essential role in early murine embryonic development but is dispensable in ventricular cardiomyocytes. Mol Cell Biol (2005) 1.27
Embryonic survival and severity of cardiac and craniofacial defects are affected by genetic background in fibroblast growth factor-16 null mice. DNA Cell Biol (2010) 1.22
Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death. Hum Mol Genet (2008) 1.22
Electrical self-healing of mechanically damaged zinc oxide nanobelts. Nano Lett (2010) 1.21
Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res (2010) 1.18
Activation of extracellular-signal regulated kinase (ERK1/2) by fluid shear is Ca(2+)- and ATP-dependent in MC3T3-E1 osteoblasts. Bone (2007) 1.16
IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation. J Exp Med (2005) 1.15
Nuclear Ca2+ sparks and waves mediated by inositol 1,4,5-trisphosphate receptors in neonatal rat cardiomyocytes. Cell Calcium (2007) 1.14
Flexible Zn2SnO4/MnO2 core/shell nanocable-carbon microfiber hybrid composites for high-performance supercapacitor electrodes. Nano Lett (2011) 1.14
Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol (2010) 1.13
The formin-homology-domain-containing protein FHOD1 enhances cell migration. J Cell Sci (2003) 1.13
Characterization and in vivo functional analysis of splice variants of cypher. J Biol Chem (2002) 1.13
Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury. Arthritis Rheum (2013) 1.12
Positive allosteric modulators of the human sweet taste receptor enhance sweet taste. Proc Natl Acad Sci U S A (2010) 1.11
Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis. PLoS One (2012) 1.11
New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology (2003) 1.10
Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. Int J Cancer (2009) 1.10
Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J Bone Miner Res (2002) 1.10
Young's modulus of ZnO nanobelts measured using atomic force microscopy and nanoindentation techniques. Nanotechnology (2006) 1.09
A novel fatty acid-binding protein (FABP) gene resulting from tandem gene duplication in mammals: transcription in rat retina and testis. Genomics (2008) 1.08
Catalytic asymmetric [3+2] cycloaddition of azomethine ylides. Development of a versatile stepwise, three-component reaction for diversity-oriented synthesis. J Am Chem Soc (2003) 1.08
Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother (2012) 1.07
A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J Bone Miner Res (2003) 1.07
RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res (2008) 1.06
Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res (2011) 1.05
The effect of citric acid added to hydroxypropyl methylcellulose (HPMC) matrix tablets on the release profile of vinpocetine. Drug Dev Ind Pharm (2004) 1.02
Origin of flaw-tolerance in nacre. Sci Rep (2013) 1.02
Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. Toxicol Sci (2011) 1.02
Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology (2011) 1.00
Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR. Clin Chim Acta (2011) 1.00
Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone (2010) 1.00
Catalyst-free synthesis, structural, and mechanical characterization of twinned Mg2B2O5 nanowires. Nano Lett (2008) 1.00
Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone (2011) 1.00
Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. J Clin Virol (2010) 1.00
New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification. J Bone Miner Res (2009) 0.99
One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. J Bone Miner Res (2009) 0.99
Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone (2009) 0.98
Solution-processed hybrid cathode interlayer for inverted organic solar cells. ACS Appl Mater Interfaces (2013) 0.98
Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther (2010) 0.97
Molecules mimicking Smad1 interacting with Hox stimulate bone formation. J Biol Chem (2003) 0.97
Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci (2008) 0.96
Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res (2014) 0.96
Graphene-based composite materials beneficial to wound healing. Nanoscale (2012) 0.96
Bone morphogenetic protein-9 induces osteogenic differentiation of rat dental follicle stem cells in P38 and ERK1/2 MAPK dependent manner. Int J Med Sci (2012) 0.96